Kyverna Therapeutics, Inc. (KYTX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

SA Transcripts 162.21K Followers Follow Kyverna Therapeutics, Inc. ( KYTX ) Morgan Stanley 24th Annual Global Healthcare Conference September 14, 2026 4:05 PM EDT Company Participants Warner Biddle - CEO & Director Conference Call Participants Michael Ulz - Morgan Stanley, Research Division Presentation Michael Ulz Morgan Stanley, Research Division All right. Good afternoon, everyone, and thanks for joining us at the Morgan Stanley Global Healthcare Conference. I'm Mike Ulz, one of the biotech analysts, and it's my pleasure to introduce Warner Biddle, CEO of Kyverna Therapeutics. And just as a quick reminder, the format for today is a fireside chat, so if anyone in the audience has a question, please raise your hand and we'll get it looped into our discussion here. But before we get started, I just need to read a quick disclosure. For important disclosures, please see the Morgan Stanley Research Disclosure website at www.morganstanley.com/researchdisclosures. If you have any questions, please reach out to your Morgan Stanley sales representative. And with that, I'll turn it over to Warner and if you want to make some introductory comments, and then we can hop into the Q&A. Warner Biddle CEO & Director Sure, Mike. Thanks very much for hosting us. It's been a great day so far. And yes, I'd like to just start off by saying Kyverna is really excited about the tremendous progress we're making. We're leading the world in bringing cell therapy to autoimmune patients, starting with our first indication with Stiff Person syndrome, but we're on track to finish filing our BLA as of Q4 of this year, which would put us on track to be the first approved therapy in this terrible condition that has no approved therapies. But more importantly, it puts us on track to be the first cell therapy company anywhere in the world with an approved therapy in autoimmune diseases.